New England Biolabs Expands Genomics Toolkit with seqWell Transposase Partnership

  • New England Biolabs (NEB) and seqWell launched a strategic partnership on October 15, 2026, with NEB gaining co-exclusive rights to sell and manufacture seqWell's TnX Transposase (Unloaded).
  • TnX Transposase (Unloaded) enables custom transposome assembly for flexible, platform-agnostic genomic workflows.
  • NEB will integrate TnX into its existing product portfolio, addressing lot variability issues common in unloaded Tn5 transposases.
  • The product is now available through NEB's distribution channels with optimized protocols for research applications.

This partnership aligns with the growing demand for scalable, high-performance genomic tools, particularly as single-cell and multi-omics research expand. NEB's manufacturing expertise and seqWell's transposase technology create a formidable combination in the competitive next-generation sequencing (NGS) library preparation space. The deal underscores the industry's shift toward modular, customizable solutions for complex genomic workflows.

Market Adoption
How quickly researchers will integrate TnX Transposase into existing workflows, particularly in single-cell and custom assay development.
Competitive Positioning
Whether NEB can leverage its manufacturing scale to outpace competitors in the transposase market.
Technical Validation
The pace at which third-party studies confirm TnX's reproducibility and performance advantages over existing solutions.